Definium Therapeutics Inc (DFTX) FinancialsDFTXDefinium Therapeutics Inc

Evaluating the bottom line, Definium Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.09%, provide a clear picture of how effectively DFTX converts its operational activities into shareholder value.

In the context of the broader market, DFTX competes directly with industry leaders such as TVTX and PTCT. With a market capitalization of $4.96B, it holds a significant position in the sector. When comparing efficiency, DFTX's gross margin of N/A stands against TVTX's 96.45% and PTCT's 91.19%. Such benchmarking helps identify whether Definium Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Definium has shown a significant increase in total equity, reaching 918,679,000 USD in Q2 2026, indicating a strong financial position despite ongoing net losses. The current ratio remains healthy at 6.95, suggesting good liquidity.